Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: A critical review

Expert Opinion on Investigational Drugs

Volumn 21, Issue 10, 2012, Pages 1463-1474

  Jendle, Johan ^a   Martin, Sherry A ^b   Milicevic, Zvonko ^b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Combination therapy; GLP 1; GLP 1 analog; Insulin; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RECOMBINANT HUMAN INSULIN; SEMIGLUTIDE; SHORT ACTING DRUG; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; U 500; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADD ON THERAPY; CLINICAL PRACTICE; CONSTIPATION; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; INTENSIVE CARE UNIT; MORBIDITY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREAS ISLET CELL FUNCTION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SIDE EFFECT; SLOW RELEASE FORMULATION; STOMACH MOTILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84866534106     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.707190     Document Type: Review

References (62)

1. Viberti G, Lachin J, Holman R, et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 2006;23:1289-94 (Pubitemid 44787790)
2. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
4. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005;36:197-209 (Pubitemid 40755133)
5. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-9 (Pubitemid 38141937)
6. Lamberts EJ, Nijpels G, Welschen LM, et al. Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2011;20:351-8
7. Goldman-Levine JD. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011;31:44S-53S
8. Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010;44:1294-300
9. Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Technol Ther 2011;13:873-81
10. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
11. Iltz JL, Baker DE, Setter SM, Keith CR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006;28:652-65 (Pubitemid 44067260)
12. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705-14
13. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10
14. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
15. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
16. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
17. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl 3):26-34
18. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997;105:187-95 (Pubitemid 27385211)
19. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30 (Pubitemid 350005153)
20. Riddle MC, Rosenstock J, Gerich J. The Treat-to-target trial. Diabetes Care 2003;26:3080-6
21. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63
22. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
23. Pamphlet/product. Byetta prescribing information. Eli Lilly and Co; Indianapolis, IN: 2011
24. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
25. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67
26. Pamphlet/product. Victoza prescribing information. Novo-Nordisk; Princeton, NJ: 2011
27. Pamphlet/product. Bydureon prescribing information. Amylin Pharmaceuticals; San Diego, CA: 2012
28. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
29. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
30. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011;71:1675-88
31. Davis SN, Johns D, Maggs D, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30:2767-72 (Pubitemid 350083115)
32. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-92
33. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511\23
34. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41-6
35. Price HC, Gorst C, Ayyagari U, et al. Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. Pract Diabetes 2012;29:61-4
36. Ryder R, Thong K, Cull M, et al. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int 2010;27:352-357b
37. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-10
38. Thong KY, Jose B, Blann AD, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011;93:87-91
39. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509-15
40. Bain SC, Devries JH, Seufert J, et al. 2012
41. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 2011;6:67-79
42. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61 (Pubitemid 43942931)
43. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005;28:1245-9
44. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34 (Pubitemid 44297431)
45. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-83 (Pubitemid 41368581)
46. Hermanides J, Vriesendorp TM, Bosman RJ, et al. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838-42
47. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
48. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46 (Pubitemid 36121094)
49. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67 (Pubitemid 32888861)
50. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74 (Pubitemid 44125921)
51. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
52. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-42 (Pubitemid 350172854)
53. Meneghini LF, Orozco-Beltran D, Khunti K, et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011;96:3337-53
54. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72
55. Nayak UA, Govindan J, Baskar V, et al. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687-94
56. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10
57. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011;54(Suppl):OP13
58. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
59. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
60. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
61. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-66
62. From the Global GetGoal Zealand Pharma Announces Additional Positive Results for Lixisenatide (Lyxumia® 1) from the Global GetGoal Phase III Program in Type 2 Diabetes. Zealand Pharma. 2012.Available From: Http://ir. Zealandpharma.com/releasedetail.cfm? ReleaseID=647087 [Last Accessed 19 March 2012]